%0 Journal Article %A Nobunori Takahashi %A Toshihisa Kojima %A Atsushi Kaneko %A Daihei Kida %A Yuji Hirano %A Takayoshi Fujibayashi %A Yuichiro Yabe %A Hideki Takagi %A Takeshi Oguchi %A Hiroyuki Miyake %A Takefumi Kato %A Tsuyoshi Watanabe %A Masatoshi Hayashi %A Yasuhide Kanayama %A Koji Funahashi %A Shuji Asai %A Yutaka Yoshioka %A Toki Takemoto %A Kenya Terabe %A Nobuyuki Asai %A Naoki Ishiguro %T Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks %D 2015 %R 10.3899/jrheum.141288 %J The Journal of Rheumatology %P 786-793 %V 42 %N 5 %X Objective. Our study aimed to evaluate the longterm efficacy and safety of abatacept (ABA), and to explore factors that increase its longterm efficacy in patients with rheumatoid arthritis (RA) treated in routine clinical practice. Methods. There were 231 participants with RA treated with ABA who were prospectively registered in a Japanese multicenter registry. They were followed up for at least 52 weeks. Results. Mean age of the patients was 64.3 years, mean disease duration was 12.1 years, mean 28-joint Disease Activity Score (DAS28)-C-reactive protein was 4.49, and 48.5% of patients were concomitantly treated with methotrexate (MTX). Overall retention rate of ABA was 77.1% at 52 weeks; 14.8% of patients discontinued because of inadequate response and 3.5% because of adverse events. The proportion of patients achieving DAS28-defined low disease activity (LDA) significantly increased from baseline to 52 weeks (7.3% to 43.8%, p < 0.01); 40.9% of patients who did not achieve LDA at 24 weeks had more than 1 categorical improvement in DAS28-defined disease activity at 52 weeks. Multivariate logistic regression revealed concomitant MTX use to be an independent predictor of the categorical improvement in DAS28-defined disease activity from 24 to 52 weeks (adjusted OR 3.124, p = 0.010). Conclusion. In routine clinical practice, ABA demonstrated satisfactory clinical efficacy and safety in patients with established RA for 52 weeks. The clinical efficacy of ABA increased with time even after 24 weeks, and this was strongly influenced by concomitant MTX use. Our study provides valuable real-world findings on the longterm management of RA with ABA. %U https://www.jrheum.org/content/jrheum/42/5/786.full.pdf